hepsulfam

Hepsulfam is an **alkylating agent** developed as a structural analog of busulfan. It belongs to the family of **alkylsulfonate alkylating agents** and is classified as a **bisulfamic ester**. The drug was developed by **Mayo Clinic** and underwent Phase I clinical trials as an anticancer agent. The compound works through an **alkylating mechanism** where it forms covalent linkages with nucleophilic centers in DNA, resulting in multiple forms of DNA damage including depurination, base miscoding, strand scission, and DNA-DNA and DNA-protein cross-linking, ultimately leading to cytotoxicity[5]. Hepsulfam demonstrated **superior cytotoxicity compared to busulfan** at equimolar concentrations across multiple human tumor cell lines, including lung, melanoma, kidney, breast, colon, ovary, and brain tumor cells[1]. The drug showed marked dose-dependent cytotoxicity with continuous exposure, though cytotoxicity was not observed following one-hour exposures[1]. The compound has a molecular formula of C7H18N2O6S2 with a molecular mass of 290.36 and a melting point of 94-95°C[2]. Its development status is **discontinued**, with the highest R&D phase reached being Phase I[3].

Other names

Sulfamic acid, S,S'-1,7-heptanediyl esterSulfamic acid, 1,7-heptanediyl ester1,7-Heptanediyl sulfamate1,7-Heptanediol disulfamateZINC01574758ZINC-01574758ZINC 01574758